Session Type
Meeting
Search Results for Emboli
Abstract Number: 118
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Guidelines for peripherally inserted central catheters (PICCs) recommend avoiding insertion if the anticipated use is 5 or fewer days. However, short-term PICC use is common in hospitals. We sought to identify patient-, provider- and device-characteristics associated with short-term PICC use. Methods: Between January 2014 and June 2016, trained abstractors at each of 51 Michigan […]
Abstract Number: 118
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Guidelines recommend pharmacologic venous thromboembolism (VTE) prophylaxis for high risk hospitalized medical patients that do not have an elevated bleeding risk. A systematic review of randomized trials estimates the overall bleeding risk with pharmacologic prophylaxis to be low, at 1/1000 (0.1%). However, it is unclear if the bleeding events were related to pharmacologic prophylaxis […]
Abstract Number: 119
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Guidelines and quality performance measures recommend venous thromboembolism (VTE) prophylaxis in patients hospitalized with stroke if they have paralysis or are confined to bed and also recommend that all hospitalized medical patients have VTE risk assessment performed. The Padua Prediction Score is a validated VTE risk prediction model for medical patients based on clinical […]
Abstract Number: 119
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Prophylactic anticoagulation is effective at reducing the risk of venous thromboembolism (VTE), but can also increase the risk of bleeding. Whether anticoagulant prophylaxis should be modified for underweight patients to minimize bleeding complications is unknown. We sought to determine whether being underweight is associated with the risk of major bleeding in hospitalized medical patients […]
Abstract Number: 129
Hospital Medicine 2020, Virtual Competition
Background: Cancer-associated thrombosis (CAT) is a common complication in patients with malignancy. Management of venous thromboembolism (VTE), in these patients, is challenging due to the high risk of recurrence and inherent risk of bleeding in this population. Direct oral anticoagulants (DOACs) have emerged as a treatment options for CAT. As yet there have not been […]
Abstract Number: 139
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: The In-hospital Mortality for Pulmonary embolism using Claims daTa (IMPACT) rule has been validated in a number of commercial and all-payer claims databases; classifying pulmonary embolism (PE) patients into low- and higher-risk in-hospital all-cause mortality categories with a sensitivity of 87% and specificity of 47%. We sought to directly compare the accuracy of IMPACT […]
Abstract Number: 143
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Multi-lumen (ML) peripherally inserted central catheters (PICCs) are associated with increased risk of central line associated blood stream infection (CLABSI), venous thromboembolism (VTE) and increased cost compared to single lumen (SL) PICCs. Current guidelines recommend minimizing the number of PICC lumens. However, there is a paucity of literature to guide the selection of SL […]
Abstract Number: 144
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant […]
Abstract Number: 145
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant […]
Abstract Number: 145
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Chemoprophylaxis with subcutaneous heparin or low-molecular weight heparin is recommended for venous thromboembolism (VTE) prevention in appropriate medical patients. However, all doses are not always administered and the consequences are unclear. We sought to determine if there is a relationship between missed and/or refused doses and development of in-hospital VTEs. Methods: The study is […]